This is a discussion on FDA Drug Safety Communication: Update: Follow up to the Public Health Alert about Changes to the Heparin Sodium USP Mono within the FDA News forum, part of the Industry News and Updates category; Laboratory studies performed at the request of the U.S. Food and Drug Administration (FDA) have shown that Heparin Sodium, ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
|
|||
|
Laboratory studies performed at the request of the U.S. Food and Drug Administration (FDA) have shown that Heparin Sodium, USP (heparin) made under the new United States Pharmacopeia (USP) Monograph ("new heparin") has approximately 10% less blood-thinning (anticoagulant) activity compared to heparin prepared using the previous ("old") USP Monograph.
More... |
![]() |
| Thread Tools | |
| Display Modes | |
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vy | industry_news | FDA News | 0 | 12-22-2009 12:46 PM |
| FDA Public Health Alert: Change in Heparin USP Monograph | industry_news | FDA News | 0 | 10-01-2009 02:33 PM |
| FDA Public Health Alert: Potential Medication Errors with Tamiflu for Oral Suspension | industry_news | FDA News | 0 | 09-24-2009 05:27 PM |
| Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) | industry_news | FDA News | 0 | 01-13-2009 03:42 PM |
| Drug Shortage: Heparin sodium injection multidose and single dose vials, heparin flus | industry_news | FDA News | 0 | 03-04-2008 09:18 AM |